Item 2.02 - Results of Operations and Financial Condition: Illumina issued a press release on February 5, 2026, announcing financial results for the fourth quarter and fiscal year ended December 28, 2025 Press Release Attached as Exhibit 99.1: The full text of the earnings announcement is included as an exhibit to this 8-K filing Non-Filed Information: The information furnished under Item 2.02…

Our analysis rates this filing CAUTIOUS. Illumina faces a moderately elevated concern profile driven by three material developments: (1) a structural collapse in China revenue representing a significant geographic revenue loss with unclear resolution, (2) a deceleration in organic growth guidance to…

Concern level: HIGH (6.2/10). Key factors: China market structural collapse: 75% YoY revenue decline in Q4 2025 ($240M to $59M) represents material geopolitical/competitive headwind affecting 5-6% of total revenue with no clear recovery timeline; Organic growth deceleration: FY2026 guidance projects only 2-4% ex-China organic growth, materially below historical company performance and indicating…

Notable risk changes: China market collapse: Q4 2025 China revenue ~$59M vs ~$240M in Q4 2024 (75% decline), representing a structural shift in geographic revenue mix and geopolitical risk exposure; Organic growth deceleration: FY2026 guidance of 2-4% ex-China organic growth is materially lower than historical company performance, with acquisition-driven growth (1.5-2.0% from SomaLogic) masking underlying organic…

The model predicts ILMN will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.